Kura Oncology/$KURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kura Oncology
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Ticker
$KURA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
192
ISIN
US50127T1097
Website
Kura Oncology Metrics
BasicAdvanced
$540M
-
-$2.09
0.50
-
Price and volume
Market cap
$540M
Beta
0.5
52-week high
$23.48
52-week low
$5.41
Average daily volume
1.4M
Financial strength
Current ratio
8.068
Quick ratio
7.934
Long term debt to equity
4.261
Total debt to equity
5.311
Interest coverage (TTM)
-126.91%
Management effectiveness
Return on assets (TTM)
-19.60%
Return on equity (TTM)
-41.84%
Valuation
Price to revenue (TTM)
7.988
Price to book
1.38
Price to tangible book (TTM)
1.38
Price to free cash flow (TTM)
4.913
Growth
Earnings per share change (TTM)
-4.14%
3-year earnings per share growth (CAGR)
1.58%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Kura Oncology News
AllArticlesVideos
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
GlobeNewsWire·17 hours ago
Kura Oncology to Participate in Three Upcoming Investor Conferences
GlobeNewsWire·3 days ago
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kura Oncology stock?
Kura Oncology (KURA) has a market cap of $540M as of May 23, 2025.
What is the P/E ratio for Kura Oncology stock?
The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of May 23, 2025.
Does Kura Oncology stock pay dividends?
No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Kura Oncology dividend payment date?
Kura Oncology (KURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kura Oncology?
Kura Oncology (KURA) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.